|
|
Volumn 14, Issue 3, 2010, Pages 285-288
|
|
The evolving role of molecular diversity in drug discovery
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANSAMYCIN DERIVATIVE;
ANTIINFECTIVE AGENT;
CELL NUCLEUS RECEPTOR;
GELDANAMYCIN;
LATENT CYTOPLASMIC FACTOR;
ONCOGENIC TRANSLOCATION FUSION PROTEIN;
RESIDENT NUCLEAR RECEPTOR;
RNA;
TRANSCRIPTION FACTOR;
UNCLASSIFIED DRUG;
BIODIVERSITY;
BIOSYNTHESIS;
DISEASE COURSE;
DNA LIBRARY;
DNA SEQUENCE;
DRUG DEVELOPMENT;
DRUG INDUSTRY;
DRUG INFORMATION;
DRUG TARGETING;
EDITORIAL;
FLUORESCENCE;
GENETIC ENGINEERING;
GENOMICS;
HIGH THROUGHPUT SCREENING;
MICROARRAY ANALYSIS;
MOLECULAR EVOLUTION;
MOLECULAR PROBE;
PROTEIN DNA INTERACTION;
PROTEIN PROTEIN INTERACTION;
REGULATORY RNA SEQUENCE;
ANIMALS;
DRUG DISCOVERY;
GENOMICS;
HIGH-THROUGHPUT SCREENING ASSAYS;
HUMANS;
PROTEIN INTERACTION DOMAINS AND MOTIFS;
PROTEIN INTERACTION MAPPING;
SEQUENCE ANALYSIS, DNA;
|
|
EID: 77952552279
PISSN: 13675931
EISSN: None
Source Type: Journal
DOI: 10.1016/j.cbpa.2010.05.001 Document Type: Editorial |
|
Times cited : (10)
|
|
References (1)
|
